AbbVie (ABBV) looks to new drugs to boost sales following Humira competition - WSJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| AbbVie (NYSE: ABBV) | Delayed: 282.75 -6.33 (2.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $289.08 | 52 Week High | $68.12 | |||
| Open | $287.63 | 52 Week Low | $50.71 | |||
| Day High | $289.00 | P/E | 61.33 | |||
| Day Low | $282.75 | EPS | $4.61 | |||
| Volume | 1,399,021 | |||||
